Search

Your search keyword '"Bury, Roxana"' showing total 18 results
Start Over Author "Bury, Roxana"
18 results on '"Bury, Roxana"'

4. The Presence of ANCA in IgA Crescentic Nephropathy Does Not Lead to Worse Prognosis with Intensive Rescue Treatment

Author

Agraz, Irene, primary, Castañeda, Zaira, additional, Sanz-Martínez, María Teresa, additional, Gabaldón, Alejandra, additional, Bermejo, Sheila, additional, Viñas Gimenez, Laura, additional, Bury, Roxana, additional, Bolufer, Mónica, additional, López-Martínez, Marina, additional, Ramos, Natalia, additional, Bestard, Oriol, additional, and Soler, María José, additional

Published
2022
Full Text
View/download PDF

6. MO151CLINICAL COURSE AND OUTCOMES OF COVID-19 PATIENTS WITH BIOPSY-PROVEN GLOMERULAR AND TUBULAR KIDNEY DISEASE. LOW HEMOGLOBIN LEVELS AS A RISK FACTOR FOR MORTALITY

Author

León Román, Juan, primary, García Carro, Clara, additional, Agraz, Irene, additional, Toapanta, Néstor, additional, Vergara Arana, Ander, additional, Gabaldon, Alejandra, additional, Torres Rodriguez, Irina, additional, Bury, Roxana, additional, Baldallo, Cinthia, additional, Seron Micas, Daniel, additional, and Soler, María José, additional

Published
2021
Full Text
View/download PDF

7. MO160COVID-19 INFECTION AND ACUTE TUBULOINTERSTITIAL NEPHRITIS

Author

León, Juan Carlos, primary, Agraz, Irene, additional, Vergara Arana, Ander, additional, Ramos Terrada, Natalia, additional, García Carro, Clara, additional, Gabaldon, Alejandra, additional, Bury, Roxana, additional, Bermejo Garcia, Sheila, additional, Seron Micas, Daniel, additional, and Soler, María José, additional

Published
2021
Full Text
View/download PDF

8. MO141ACUTE KIDNEY INJURY AS A RISK FACTOR FOR MORTALITY IN ONCOLOGICAL PATIENTS RECEIVING CHECK-POINT INHIBITORS

Author

García Carro, Clara, primary, Bolufer, Mónica, additional, Bury, Roxana, additional, CAstañeda, Zaira, additional, Muñoz, Eva, additional, Felip, Enriqueta, additional, Lorente, David, additional, Carreras, Maria Jose, additional, Gabaldon, Alejandra, additional, Agraz, Irene, additional, Seron Micas, Daniel, additional, and Soler, María José, additional

Published
2021
Full Text
View/download PDF

9. MO308COULD THE PRESENCE OF ANCAS IN IGA NEPHROPATHY WITH CRESCENTS HAVE A CLINICAL IMPLICATION?

Author

Castañeda Amado, Zaira, primary, Gabaldon, Alejandra, additional, Sanz, María Teresa, additional, Bury, Roxana, additional, Baldallo, Cinthia, additional, Zuñiga, Jose, additional, León, Juan Carlos, additional, Sanchez, Cesar, additional, Vergara, Ander, additional, Bermejo, Sheila, additional, Soler, María José, additional, Seron Micas, Daniel, additional, and Agraz, Irene, additional

Published
2021
Full Text
View/download PDF

10. Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors.

Author

García-Carro, Clara, Bolufer, Mónica, Bury, Roxana, Castañeda, Zaira, Muñoz, Eva, Felip, Enriqueta, Lorente, David, Carreras, María Josep, Gabaldon, Alejandra, Agraz, Irene, Serón, Daniel, and Soler, María José

Subjects
INJURY risk factors, MORTALITY risk factors, ACUTE kidney failure, CANCER patients, DISEASE risk factors
Abstract

Background Checkpoint inhibitors (CPIs) have drastically improved metastatic cancer outcomes. However, immunotherapy is associated with multiple toxicities, including acute kidney injury (AKI). Data about CPI-related AKI are limited. Our aim was to determine risk factors for CPI-related AKI as well as its clinical characteristics and its impact on mortality in patients undergoing immunotherapy. Methods All patients under CPI at our centre between March 2018 and May 2019 and with a follow-up through April 2020 were included. Demographic, clinical and laboratory data were collected. AKI was defined according to the Kidney Disease: Improving Global Outcomes guidelines. We performed a logistic regression model to identify independent risk factors for AKI and actuarial survival analysis to establish risk factors for mortality in this population. Results A total of 759 patients were included, with a median age of 64 years. A total of 59% were men and baseline median creatinine was 0.80 mg/dL. The most frequent malignancy was lung cancer and 56% were receiving anti-programmed death protein 1 (PD-1). About 15.5% developed AKI during the follow-up. Age and baseline kidney function were identified as independent risk factors for CPI-related AKI. At the end of follow-up, 52.3% of patients had died. The type of cancer (not melanoma, lung or urogenital malignance), type of CPI (not cytotoxic T-lymphocyte-associated protein 4, PD-1, programmed death-ligand 1 or their combination) and the presence of an episode of AKI were identified as risk factors for mortality. Conclusions A total of 15.5% of patients under immunotherapy presented with AKI. A single AKI episode was identified as an independent risk factor for mortality in these patients and age and baseline renal function were risk factors for the development of AKI. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

11. Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors

Author

García-Carro, Clara, primary, Bolufer, Mónica, additional, Bury, Roxana, additional, Castañeda, Zaira, additional, Muñoz, Eva, additional, Felip, Enriqueta, additional, Lorente, David, additional, Carreras, María Josep, additional, Gabaldon, Alejandra, additional, Agraz, Irene, additional, Serón, Daniel, additional, and Soler, María José, additional

Published
2021
Full Text
View/download PDF

17. Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience.

Author

Oleas, Diana, Bolufer, Mónica, Agraz, Irene, Felip, Enriqueta, Muñoz, Eva, Gabaldón, Alejandra, Bury, Roxana, Espinel, Eugenia, Serón, Daniel, García-Carro, Clara, and Soler, María José

Subjects
IMMUNE checkpoint inhibitors, INTERSTITIAL nephritis, DRUG side effects, ACUTE kidney failure, RENAL biopsy, CHRONIC kidney failure
Abstract

Background Checkpoint inhibitors (CPIs) are used to treat solid organ metastatic malignancies. They act by triggering a vigorous immune response against tumoural cells, preventing their proliferation and metastasis. However, this is not a selective response and can cause immune-related adverse events (irAEs). The kidney can potentially be damaged, with an incidence of irAEs of 1–4%. The most frequent type of toxicity described is acute interstitial nephritis (AIN). Methods We conducted a study of patients with solid organ metastatic malignancies treated with immunotherapy who developed acute renal injury and underwent kidney biopsy in the last 14 months at the Vall d'Hebron University Hospital. Results In all, 826 solid organ malignancies were treated with immunotherapy in our centre, 125 of them (15.1%) developed acute kidney injury (AKI), 23 (18.4% of AKI) visited the nephrology department and 8 underwent kidney biopsy. The most frequent malignancy was lung cancer, in five patients (62%), followed by two patients (25%) with melanoma and one patient (12%) with pancreatic cancer. Four patients (50%) had already received previous oncological therapy, and for the remaining four patients (50%), CPI was the first-line therapy. Five patients (62%) were treated with anti-programmed cell death protein 1, three patients (37%) received anti-programmed death ligand 1 and two (25%) patients were treated in combination with anti-cytotoxic T-lymphocyte antigen 4. The time between the start of CPI and the onset of the AKI ranged from 2 to 11 months. The most frequent urine findings were subnephrotic-range proteinuria, with a mean protein:creatinine ratio of 544 mg/g (standard deviation 147) and eosinophiluria. All patients were biopsied after being diagnosed with AIN. Three patients (37%) received treatment with pulses of methylprednisolone 250–500 mg/day and five patients (62%) received prednisone 1 mg/kg/day. Seven patients (87%) experienced recovery of kidney function and one patient (12%) progressed to chronic kidney disease. Conclusions We report on eight patients with CPI-related AIN diagnosed in the last 14 months at our centre. The novel immunotherapy treatment of metastatic solid organ malignancies carries a higher risk of irAEs. The kidney is one of the most commonly affected organs, frequently presenting as an AIN and exhibiting a favourable response to steroid treatment. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

18. FP104UTILITY OF TRANSYUGULAR RENAL BIOPSY AS AN ALTERNATIVE TO PERCUTANEOUS BIOPSY

Author

Bolufer, Mónica, primary, Soler, Maria José, additional, Agraz, Irene, additional, Garcia-Carro, Clara, additional, Jaramillo, Juliana, additional, Arredondo, Karla, additional, Bury, Roxana, additional, Ramos, Natalia, additional, Azancot, M Antonia, additional, Gabaldón, Alejandra, additional, Perez, Mercedes, additional, Espinel, Eugenia, additional, and Seron, Daniel, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results